Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
Epigenetics & Chromatin
|
March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learned
Stephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Cell Chemical Biology
|
March 7, 2017
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells
Anthony Tumber, Andrea Nuzzi, Edward S Hookway, et al.
Nature
|
October 4, 2014
Kruidenier et al. reply
Laurens Kruidenier, Chun-wa Chung, Zhongjun Cheng, et al.
Nature Cancer
|
April 18, 2024
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
Hannah Lawson, James P Holt-Martyn, Vilma Dembitz, et al.
Nature
|
July 31, 2012
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier, Chun-wa Chung, Zhongjun Cheng, et al.
Nature Communications
|
February 25, 2026
Structural basis of the promiscuity of the unusual Fe(II) and 2-oxoglutarate dependent human aspartate/asparagine-β-hydroxylase
Mariska de Munnik, Amelia Brasnett, Tiankun Zhou, et al.
Scientific Reports
|
June 25, 2021
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Martin A Redhead, C David Owen, Lennart Brewitz, et al.
Scientific Reports
|
September 29, 2021
Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Martin A Redhead, C David Owen, Lennart Brewitz, et al.
European Journal of Medicinal Chemistry
|
June 4, 2019
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays
Yann-Vaï Le Bihan, Rachel M Lanigan, Butrus Atrash, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
Epigenetics & Chromatin
|
March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learned
Stephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Cell Chemical Biology
|
March 7, 2017
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells
Anthony Tumber, Andrea Nuzzi, Edward S Hookway, et al.
Nature
|
October 4, 2014
Kruidenier et al. reply
Laurens Kruidenier, Chun-wa Chung, Zhongjun Cheng, et al.
Nature Cancer
|
April 18, 2024
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
Hannah Lawson, James P Holt-Martyn, Vilma Dembitz, et al.
Nature
|
July 31, 2012
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier, Chun-wa Chung, Zhongjun Cheng, et al.
Nature Communications
|
February 25, 2026
Structural basis of the promiscuity of the unusual Fe(II) and 2-oxoglutarate dependent human aspartate/asparagine-β-hydroxylase
Mariska de Munnik, Amelia Brasnett, Tiankun Zhou, et al.
Scientific Reports
|
June 25, 2021
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Martin A Redhead, C David Owen, Lennart Brewitz, et al.
Scientific Reports
|
September 29, 2021
Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Martin A Redhead, C David Owen, Lennart Brewitz, et al.
European Journal of Medicinal Chemistry
|
June 4, 2019
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays
Yann-Vaï Le Bihan, Rachel M Lanigan, Butrus Atrash, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Page
of 11